tradingkey.logo

Nexalin Technology Inc

NXL
查看详细走势图
0.515USD
-0.105-16.95%
收盘 02/06, 16:00美东报价延迟15分钟
9.37M总市值
亏损市盈率 TTM

Nexalin Technology Inc

0.515
-0.105-16.95%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-16.95%

5天

-9.67%

1月

-27.68%

6月

-42.79%

今年开始到现在

-7.72%

1年

-86.16%

查看详细走势图

TradingKey Nexalin Technology Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Nexalin Technology Inc当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力稳定。当前估值合理,在医疗设备与耗材行业排名116/205位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价4.00。中期看,股价处于下降通道。近一个月,市场表现非常差,但技术面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Nexalin Technology Inc评分

相关信息

行业排名
116 / 205
全市场排名
300 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Nexalin Technology Inc亮点

亮点风险
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
业绩增长期
公司处于发展阶段,最新年度总收入168.72K美元
利润高增长
公司净利润处于行业前列,最新年度总收入168.72K美元
估值高估
公司最新PE估值-0.80,处于3年历史高位
机构减仓
最新机构持股722.74K股,环比减少52.01%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值177.92K
活跃度增加
近期活跃度增加,过去20天平均换手率1.05

分析师目标

根据 1 位分析师
买入
评级
4.000
目标均价
+676.85%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Nexalin Technology Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Nexalin Technology Inc简介

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
公司代码NXL
公司Nexalin Technology Inc
CEOWhite (Mark)
网址https://nexalin.com
KeyAI